The HDAC6i ACY1215 improved survival in mice with ARID1A mutated ovarian clear cell carcinoma41 and ACY1215 combined with anti-PD-L1 immune checkpoint blockade in ARID1A mutated murine ovarian clear cell carcinoma reduced tumor burden and improved survival42. Here, ARID1A is linked to neoplasm.